Page 1 | Search Results | Blood | American Society of Hematology

1-5 of 5

Sort by

Sort Order Select

Journal Articles

Limited clinical relevance of imaging techniques in the follow-up of patients with advanced chronic lymphocytic leukemia: results of a meta-analysis

Barbara F. Eichhorst, Kirsten Fischer, Anna-Maria Fink, Thomas Elter, Clemens M. Wendtner, Valentin Goede, Manuela Bergmann, Stephan Stilgenbauer, Georg Hopfinger, Matthias Ritgen, Jasmin Bahlo, Raymonde Busch, Michael Hallek, for the German CLL Study Group (GCLLSG)

Blood (2011) 117 (6): 1817–1821.

https://doi.org/10.1182/blood-2010-04-282228

Published: 2011

Includes: Supplemental data

Journal Articles

Bendamustine Combined with Rituximab (BR) in First-Line Therapy of Advanced CLL: A Multicenter Phase II Trial of the German CLL Study Group (GCLLSG).

Kirsten Fischer, MD, Paula Cramer, MD, Stephan Stilgenbauer, MD, Raymonde Busch, Leopold Balleisen, MD, Julia Kilp, MD, Anna-Maria Fink, MD, Sebastian Boettcher, MD, Matthias Ritgen, MD, Michael Kneba, MD, PhD, Peter Staib, MD, Hartmut Döhner, MD, Silke Schulte, Barbara F. Eichhorst, MD, Michael Hallek, MD, Clemens-Martin Wendtner, MD, the German CLL Study Group (GCLLSG)

Blood (2009) 114 (22): 205.

https://doi.org/10.1182/blood.V114.22.205.205

Published: 2009

Journal Articles

First-line therapy with fludarabine compared with chlorambucil does not result in a major benefit for elderly patients with advanced chronic lymphocytic leukemia

Blood (2009) 114 (16): 3382–3391.

https://doi.org/10.1182/blood-2009-02-206185

Published: 2009

Includes: Supplemental data

Journal Articles

Dose Escalation Study To Evaluate Dose Limiting Toxicity (DLT), Maximum Tolerated Dose (MTD) and Safety of Alemtuzumab for Consolidation Therapy in Patients with Chronic Lymphoycytic Leukemia: Phase I/II Trial of the German CLL Study Group (GCLLSG).

Kirsten Fischer, MD, Carmen D. Schweighofer, MD, Matthias Ritgen, MD, Sebastian Boettcher, MD, Elena Scharf, Barbara F. Eichhorst, MD, Raymonde Busch, Wolfgang Abenhardt, MD, Michael Kneba, MD, Michael Hallek, MD, Clemens-Martin Wendtner, MD, the German CLL Study Group (GCLLSG)

Blood (2007) 110 (11): 2053.

https://doi.org/10.1182/blood.V110.11.2053.2053

Published: 2007

Journal Articles

Bendamustine in Combination with Rituximab (BR) for Patients with Relapsed Chronic Lymphocytic Leukemia (CLL): A Multicentre Phase II Trial of the German CLL Study Group (GCLLSG).

Kirsten Fischer, MD, Stephan Stilgenbauer, MD, Carmen D. Schweighofer, MD, Jasmin Renschler, Raymonde Busch, Michael Kiehl, MD, Leopold Balleisen, MD, Michael Eckart, MD, Anna M. Fink, MD, Sebastian Boettcher, MD, Matthias Ritgen, MD, Michael Kneba, MD, Peter Staib, MD, Hartmut Doehner, MD, Barbara F. Eichhorst, MD, Michael Hallek, MD, Clemens-Martin Wendtner, MD, the German CLL Study Group (GCLLSG)

Blood (2007) 110 (11): 3106.

https://doi.org/10.1182/blood.V110.11.3106.3106

Published: 2007

NARROW

Limited clinical relevance of imaging techniques in the follow-up of patients with advanced chronic lymphocytic leukemia: results of a meta-analysis

Bendamustine Combined with Rituximab (BR) in First-Line Therapy of Advanced CLL: A Multicenter Phase II Trial of the German CLL Study Group (GCLLSG).

First-line therapy with fludarabine compared with chlorambucil does not result in a major benefit for elderly patients with advanced chronic lymphocytic leukemia

Dose Escalation Study To Evaluate Dose Limiting Toxicity (DLT), Maximum Tolerated Dose (MTD) and Safety of Alemtuzumab for Consolidation Therapy in Patients with Chronic Lymphoycytic Leukemia: Phase I/II Trial of the German CLL Study Group (GCLLSG).

Bendamustine in Combination with Rituximab (BR) for Patients with Relapsed Chronic Lymphocytic Leukemia (CLL): A Multicentre Phase II Trial of the German CLL Study Group (GCLLSG).

Email alerts

ASH Publications

American Society of Hematology

Limited clinical relevance of imaging techniques in the follow-up of patients with advanced chronic lymphocytic leukemia: results of a meta-analysis

Bendamustine Combined with Rituximab (BR) in First-Line Therapy of Advanced CLL: A Multicenter Phase II Trial of the German CLL Study Group (GCLLSG).

First-line therapy with fludarabine compared with chlorambucil does not result in a major benefit for elderly patients with advanced chronic lymphocytic leukemia

Dose Escalation Study To Evaluate Dose Limiting Toxicity (DLT), Maximum Tolerated Dose (MTD) and Safety of Alemtuzumab for Consolidation Therapy in Patients with Chronic Lymphoycytic Leukemia: Phase I/II Trial of the German CLL Study Group (GCLLSG).

Bendamustine in Combination with Rituximab (BR) for Patients with Relapsed Chronic Lymphocytic Leukemia (CLL): A Multicentre Phase II Trial of the German CLL Study Group (GCLLSG).

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only